--- title: "ABL Diagnostics: Availability of the 2025 Annual Financial Report" type: "News" locale: "en" url: "https://longbridge.com/en/news/285629321.md" description: "ABL Diagnostics has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF). The report can be accessed on their website. The Board of Directors approved the financial statements and scheduled an Ordinary and Extraordinary General Meeting for June 30, 2026. ABL Diagnostics specializes in molecular biology tests and has a diverse product portfolio, including solutions for HIV, SARS-CoV-2, and other microbiological applications. The company is listed on Euronext Paris under the ticker ABLD." datetime: "2026-05-07T22:15:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285629321.md) - [en](https://longbridge.com/en/news/285629321.md) - [zh-HK](https://longbridge.com/zh-HK/news/285629321.md) generator: "portal-rs" --- # ABL Diagnostics: Availability of the 2025 Annual Financial Report **ABL Diagnostics: Availability of the 2025 Annual Financial Report** Regulatory News: ABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF). The report can be consulted on the ABL Diagnostics website: https://www.abldiagnostics.com under the section “Newsroom – Legal & Financial News”. The Board of Directors, which met on April 30, 2025, approved the annual financial statements and decided to convene the shareholders to an Ordinary and Extraordinary General Meeting on June 30, 2026 at 11:00 a.m. at the offices of the law firm De Gaulle Fleurance & Associés, located at 9 rue Boissy d’Anglas, 75008 Paris. **About ABL Diagnostics (ABLD)** ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers: - Molecular polymerase chain reaction (PCR) detection – UltraGene, and - Genotyping by DNA sequencing – DeepChek®. ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. **An expanding portfolio of microbiology products:** - HIV – Drug resistance testing, including a whole genome kit. - SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions. - Microbiome and taxonomy – 16s/18s RNA-based analyses. - Other viral and bacterial targets – Comprehensive molecular assays. **Integrated Solutions** - Real-time syndromic PCR tests - Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis. - MediaChek® – Clinical Sample Collection Kits. ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology. **ABL Diagnostics SA** Société anonyme au capital de 1 611 465,60 euros Headquarters : 72C route de Thionville - 57140 WOIPPY 552 064 933 R.C.S. METZ Tel : +33 (0) 7 83 64 68 50 Email : **info@abldiagnostics.com** **https://www.abldiagnostics.com/** View source version on businesswire.com: https://www.businesswire.com/news/home/20260507441661/en/ ### Related Stocks - [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md) - [AXDX.US](https://longbridge.com/en/quote/AXDX.US.md) ## Related News & Research - [FDA approves Tivicay pd for youngest HIV patients](https://longbridge.com/en/news/298021068.md) - [Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?](https://longbridge.com/en/news/297787019.md) - [New HIV and Breast Cancer Wins Might Change The Case For Investing In Gilead Sciences (GILD)](https://longbridge.com/en/news/297483843.md) - [RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results](https://longbridge.com/en/news/298139566.md) - [FDA Approves Gilead's New Single Tablet HIV Regimen](https://longbridge.com/en/news/297549407.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**